Actively Recruiting
Safety Evaluation of Nogapendekin Alfa Inbakicept Anktiva for Adults with Long COVID
Led by ImmunityBio, Inc. · Updated on 2026-09-24
40
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and effectiveness of Anktiva, also known as Nogapendekin Alfa Inbakicept NAI, for treating individuals with Long COVID-19. Long COVID is defined as ongoing symptoms that persist after the initial COVID-19 infection has resolved. This Phase 2 trial aims to evaluate how participants respond to this treatment and assess any associated risks. Participants will receive 600 micrograms of Anktiva administered as a subcutaneous injection. The study follows a single-group design, where all enrolled participants receive the investigational drug. The treatment period lasts approximately 75 days, during which safety and vital signs will be closely monitored. The study focuses on recording any adverse events and changes in laboratory tests during and shortly after treatment. During the trial, participants will undergo regular assessments including blood tests to monitor lymphocyte counts, vital signs such as temperature, heart rate, blood pressure, respiratory rate, and oxygen saturation. The research team will track any treatment-related side effects through 30 days after the last dose. Participants are expected to comply with study visits and evaluations throughout the treatment period and follow-up to help understand the treatments safety profile and impact on Long COVID symptoms.
CONDITIONS
Brief Title
A Study to Examine Anktiva for the Treatment of COVID-19.
Research Team
K
Kayleigh Russell
J
Jayson Garmizo
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here